The White House is expanding its effort to lower medication costs as two more pharmaceutical companies launching on TrumpRx, the administration’s discounted prescription portal. Abbvie and Genentech are set to initiate selling popular commercial medications on the site as soon as Monday, bringing the total number of participating drugmakers to 11.
The expansion marks a significant escalation in the administration’s strategy to bypass traditional pharmacy benefit managers and provide direct, reduced-rate access to high-cost prescriptions. The move targets a specific vulnerability in the U.S. Healthcare system: the “coverage gap” where patients are either entirely uninsured or possess insurance that does not cover essential, high-cost specialty drugs.
Among the most notable additions is Abbvie, which reached an agreement with the administration in January to slash prices on some of its most widely used treatments. The company will offer Humira—a blockbuster medication used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis—at an 86% discount for eligible users.
Direct Price Reductions for High-Cost Biologics
The price drop for Humira represents one of the most aggressive reductions on the platform to date. For uninsured individuals, the cost of a Humira Pen (adalimumab) can exceed $6,900. Under the new TrumpRx arrangement, coupons will be available to bring that cost down to $950, according to a White House official.
Genentech is also joining the platform following a December agreement to lower the cost of Xofluza, a single-dose antiviral pill used for the treatment and prevention of the flu. The price for the prescription will be negotiated down to approximately $50, a significant decrease from the standard list price of $168.
Further expanding the site’s reach, the pharmaceutical company Amgen is increasing its current offerings. Amgen will now include Enbrel, used for arthritis, and Otezla, which treats plaque psoriasis, among its discounted medications on the portal.
Comparison of Key Price Adjustments
| Medication | Manufacturer | Standard Price (Uninsured) | TrumpRx Price |
|---|---|---|---|
| Humira | Abbvie | $6,900+ | $950 |
| Xofluza | Genentech | $168 | ~$50 |
Eligibility and the Insurance Gap
While the price drops are substantial, the administration clarified that these rates are not universal. The discounted prices are strictly available to patients who are uninsured or those whose insurance providers do not cover the specific medication, forcing them to pay the full list price out of pocket.
Patients with comprehensive insurance coverage generally already pay lower negotiated rates through their providers. However, for those caught in the gap, the platform serves as a direct-to-consumer relief valve. Since its launch in February, the number of discounted drugs available on TrumpRx has grown from approximately 40 to over 61 offerings.
The ‘Most-Favored-Nation’ Strategy
The growth of the platform is part of a broader policy known as “most-favored-nation” agreements. Under this model, the administration pressures pharmaceutical companies to sell medications to uninsured U.S. Consumers at the same prices available to patients in other developed nations, where government price controls often keep costs lower.
To further institutionalize these savings, a White House official said the administration is working to integrate these discounts into the “Great Healthcare Plan.” The goal of this broader proposal is to ensure that individuals on government-funded insurance can utilize copays for drugs listed on the TrumpRx site.
The implementation of this broader plan remains pending, as Congress has not yet taken up the proposal. Until such legislation is passed, the site remains a primary resource for those paying full retail prices for life-altering medications.
Disclaimer: This article is for informational purposes only and does not constitute medical or financial advice. Patients should consult with a licensed healthcare provider before changing medications or starting new treatments.
The next critical checkpoint for the program will be the potential introduction of the Great Healthcare Plan in Congress, which would determine whether these discounts can be extended to those on government insurance. Updates on the legislative status of the plan are expected as the current session progresses.
Do you have experience navigating prescription costs? Share your thoughts in the comments or share this story with someone who may be affected by these price changes.
